Tech Company Financing Transactions

Dianthus Therapeutic Funding Round

5AM Ventures, Avidity Partners and Fidelity Management & Research Company participated in a $100 million Series A funding round for Dianthus Therapeutic. The financing round was announced by the company on 5/3/2022.

Transaction Overview

Company Name
Dianthus Therapeutic
Announced On
5/3/2022
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors

5AM Ventures (Lead Investor)

Avidity Partners (Lead Investor)

Fidelity Management & Research Company (Lead Investor)

Fairmount Funds Management

Tellus BioVentures (Lonnie Moulder)

Venrock

Wedbush Securities

Proceeds Purpose
The financing will be used to expand leadership and scientific teams, advance the company's lead program, DNTH103, to the clinic this year, and to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
203 Crescent St Building 17 102B
Waltham, MA 02453
USA
Phone
(781) 795-4723
Website
www.dianthustx.com
Email Address
Undisclosed
Overview
Dianthus Therapeutics is advancing next generation complement therapeutics to deliver transformative medicines for patients with rare diseases. Our mission is to develop best-in-class, potent and selective antibodies of validated and emerging complement targets to transform the lives of people living with autoimmune diseases.
Profile
Dianthus Therapeutic LinkedIn Company Profile
Social Media
Dianthus Therapeutic Company Twitter Account
Company News
Dianthus Therapeutic News
Facebook
Dianthus Therapeutic on Facebook
YouTube
Dianthus Therapeutic on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Arino Garcia
  Arino Garcia LinkedIn Profile  Arino Garcia Twitter Account  Arino Garcia News  Arino Garcia on Facebook
Chief Medical Officer
Simrat Randhawa
  Simrat Randhawa LinkedIn Profile  Simrat Randhawa Twitter Account  Simrat Randhawa News  Simrat Randhawa on Facebook
Chief Operating Officer
Evan Thompson
  Evan Thompson LinkedIn Profile  Evan Thompson Twitter Account  Evan Thompson News  Evan Thompson on Facebook
Vice President
Robert Mcgarr
  Robert Mcgarr LinkedIn Profile  Robert Mcgarr Twitter Account  Robert Mcgarr News  Robert Mcgarr on Facebook
VP - Human Resources
Kristina Maximenko
  Kristina Maximenko LinkedIn Profile  Kristina Maximenko Twitter Account  Kristina Maximenko News  Kristina Maximenko on Facebook
VP - Operations
Rivka Gluck
  Rivka Gluck LinkedIn Profile  Rivka Gluck Twitter Account  Rivka Gluck News  Rivka Gluck on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/3/2022: Line venture capital transaction
Next: 5/3/2022: Imagene AI venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to record tech company VC transactions. VC investment data records on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.